Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib in Relapsed/Refractory Non-GCB DLBCL
NCT03145064Phase 2Completed
- Sponsor
- BeiGene
- Start
- Jun 2017
- Primary completion
- May 2019
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zanubrutinib in diffuse large B-cell lymphoma (DLBCL), sponsored by BeiGene. Primary endpoint: Overall Response Rate up to 23 months. Started Jun 2017; status: completed.
02
Drugs
zanubrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03145064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03145064.